Concepts (134)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 19 | 2025 | 786 | 3.890 |
Why?
|
| Methotrexate | 11 | 2025 | 312 | 2.290 |
Why?
|
| Antimetabolites, Antineoplastic | 9 | 2025 | 170 | 1.730 |
Why?
|
| Leukemia | 3 | 2024 | 354 | 1.420 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 9 | 2025 | 1308 | 1.300 |
Why?
|
| Lymphoma | 4 | 2024 | 315 | 1.160 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2025 | 1233 | 1.110 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 2 | 2020 | 74 | 0.950 |
Why?
|
| Allopurinol | 4 | 2023 | 77 | 0.940 |
Why?
|
| Hepatic Veno-Occlusive Disease | 2 | 2022 | 14 | 0.740 |
Why?
|
| Vincristine | 2 | 2025 | 193 | 0.710 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 4 | 2024 | 89 | 0.650 |
Why?
|
| Clinical Trials as Topic | 1 | 2024 | 1107 | 0.640 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2022 | 555 | 0.620 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2019 | 260 | 0.610 |
Why?
|
| Eosinophilia | 1 | 2020 | 103 | 0.610 |
Why?
|
| Sarcoma, Ewing | 1 | 2019 | 110 | 0.580 |
Why?
|
| Translocation, Genetic | 1 | 2020 | 348 | 0.570 |
Why?
|
| Salvage Therapy | 1 | 2019 | 174 | 0.570 |
Why?
|
| Furans | 1 | 2018 | 30 | 0.560 |
Why?
|
| Ketones | 1 | 2018 | 25 | 0.560 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2019 | 770 | 0.550 |
Why?
|
| Renal Insufficiency | 1 | 2020 | 229 | 0.550 |
Why?
|
| gamma-Glutamyl Hydrolase | 1 | 2017 | 10 | 0.550 |
Why?
|
| Child | 25 | 2025 | 25112 | 0.530 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2017 | 47 | 0.520 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2017 | 50 | 0.500 |
Why?
|
| Neoplasms | 3 | 2025 | 2841 | 0.480 |
Why?
|
| Algorithms | 3 | 2025 | 1639 | 0.480 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2017 | 248 | 0.470 |
Why?
|
| Histiocytosis, Sinus | 1 | 2015 | 32 | 0.460 |
Why?
|
| Child, Preschool | 15 | 2025 | 14375 | 0.460 |
Why?
|
| Sirolimus | 2 | 2022 | 224 | 0.460 |
Why?
|
| Bone Neoplasms | 1 | 2019 | 427 | 0.450 |
Why?
|
| Infant | 13 | 2025 | 12803 | 0.440 |
Why?
|
| Adolescent | 17 | 2025 | 19986 | 0.410 |
Why?
|
| Drug Monitoring | 3 | 2025 | 273 | 0.400 |
Why?
|
| Autoimmune Diseases | 1 | 2015 | 267 | 0.400 |
Why?
|
| Humans | 35 | 2025 | 126134 | 0.350 |
Why?
|
| Immunosuppressive Agents | 1 | 2015 | 650 | 0.350 |
Why?
|
| Genotype | 1 | 2017 | 2604 | 0.340 |
Why?
|
| Mercaptopurine | 4 | 2022 | 72 | 0.340 |
Why?
|
| Antineoplastic Agents | 2 | 2018 | 1754 | 0.330 |
Why?
|
| Azacitidine | 1 | 2010 | 51 | 0.320 |
Why?
|
| Nucleosides | 1 | 2009 | 18 | 0.320 |
Why?
|
| Lymphoma, T-Cell | 1 | 2009 | 61 | 0.300 |
Why?
|
| CpG Islands | 1 | 2010 | 333 | 0.290 |
Why?
|
| Maximum Tolerated Dose | 2 | 2019 | 172 | 0.290 |
Why?
|
| Tissue Distribution | 2 | 2019 | 364 | 0.290 |
Why?
|
| Male | 19 | 2025 | 62225 | 0.280 |
Why?
|
| Enzyme Inhibitors | 1 | 2010 | 566 | 0.260 |
Why?
|
| Promoter Regions, Genetic | 1 | 2010 | 1211 | 0.250 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2018 | 1598 | 0.250 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2016 | 1158 | 0.240 |
Why?
|
| Prognosis | 5 | 2025 | 4697 | 0.240 |
Why?
|
| Cytarabine | 2 | 2022 | 99 | 0.230 |
Why?
|
| Maintenance Chemotherapy | 2 | 2023 | 21 | 0.230 |
Why?
|
| Female | 18 | 2025 | 68037 | 0.230 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2024 | 38 | 0.220 |
Why?
|
| Follow-Up Studies | 4 | 2025 | 5107 | 0.220 |
Why?
|
| Gene Rearrangement | 2 | 2020 | 322 | 0.220 |
Why?
|
| Neoplasm, Residual | 1 | 2024 | 132 | 0.200 |
Why?
|
| DNA Methylation | 1 | 2010 | 1036 | 0.200 |
Why?
|
| Thioguanine | 2 | 2022 | 21 | 0.200 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 1 | 2022 | 18 | 0.190 |
Why?
|
| Spinal Cord Diseases | 1 | 2022 | 29 | 0.190 |
Why?
|
| Young Adult | 6 | 2025 | 9635 | 0.190 |
Why?
|
| Vidarabine | 1 | 2022 | 85 | 0.190 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2022 | 92 | 0.180 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2024 | 192 | 0.180 |
Why?
|
| Patient Selection | 1 | 2024 | 698 | 0.170 |
Why?
|
| Chemical and Drug Induced Liver Injury | 2 | 2019 | 135 | 0.160 |
Why?
|
| Down Syndrome | 1 | 2023 | 200 | 0.160 |
Why?
|
| Sodium Bicarbonate | 1 | 2020 | 55 | 0.160 |
Why?
|
| Phthalazines | 1 | 2019 | 14 | 0.160 |
Why?
|
| Antiemetics | 1 | 2017 | 22 | 0.140 |
Why?
|
| Microtubules | 1 | 2018 | 118 | 0.140 |
Why?
|
| Morpholines | 1 | 2017 | 65 | 0.130 |
Why?
|
| Hypoglycemia | 1 | 2018 | 176 | 0.130 |
Why?
|
| Pharmacogenomic Testing | 1 | 2017 | 44 | 0.130 |
Why?
|
| Vomiting | 1 | 2017 | 99 | 0.130 |
Why?
|
| Unrelated Donors | 1 | 2016 | 71 | 0.120 |
Why?
|
| Lymphocyte Transfusion | 1 | 2016 | 57 | 0.120 |
Why?
|
| Adult | 5 | 2025 | 30314 | 0.120 |
Why?
|
| Survival Rate | 1 | 2019 | 2055 | 0.110 |
Why?
|
| Point-of-Care Systems | 1 | 2017 | 193 | 0.110 |
Why?
|
| Risk Factors | 2 | 2018 | 10374 | 0.110 |
Why?
|
| Bortezomib | 2 | 2024 | 68 | 0.100 |
Why?
|
| Retrospective Studies | 6 | 2024 | 16831 | 0.100 |
Why?
|
| Mucositis | 2 | 2024 | 15 | 0.090 |
Why?
|
| Disease-Free Survival | 2 | 2024 | 902 | 0.090 |
Why?
|
| Infusions, Intravenous | 2 | 2025 | 523 | 0.080 |
Why?
|
| Leukemia, T-Cell | 1 | 2009 | 11 | 0.080 |
Why?
|
| Splenic Neoplasms | 1 | 2009 | 12 | 0.080 |
Why?
|
| DNA Modification Methylases | 1 | 2010 | 48 | 0.080 |
Why?
|
| Gene Silencing | 1 | 2010 | 224 | 0.080 |
Why?
|
| United States | 1 | 2024 | 11187 | 0.080 |
Why?
|
| Remission Induction | 1 | 2009 | 298 | 0.070 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2010 | 156 | 0.070 |
Why?
|
| Neutropenia | 2 | 2024 | 199 | 0.070 |
Why?
|
| Prospective Studies | 1 | 2018 | 6178 | 0.070 |
Why?
|
| Costa Rica | 1 | 2025 | 15 | 0.060 |
Why?
|
| Treatment Outcome | 2 | 2011 | 12393 | 0.060 |
Why?
|
| Liposomes | 1 | 2025 | 196 | 0.050 |
Why?
|
| Infant, Newborn | 1 | 2017 | 8381 | 0.050 |
Why?
|
| T-Lymphocytes | 2 | 2022 | 1706 | 0.050 |
Why?
|
| Arabinonucleosides | 1 | 2022 | 33 | 0.050 |
Why?
|
| Genome-Wide Association Study | 1 | 2010 | 1732 | 0.050 |
Why?
|
| Cell Line, Tumor | 1 | 2010 | 3474 | 0.050 |
Why?
|
| Etoposide | 1 | 2022 | 112 | 0.050 |
Why?
|
| Alanine Transaminase | 1 | 2022 | 154 | 0.050 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2022 | 329 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2010 | 4894 | 0.040 |
Why?
|
| Cyclophosphamide | 1 | 2022 | 425 | 0.040 |
Why?
|
| Phosphoproteins | 1 | 2022 | 423 | 0.040 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2022 | 415 | 0.040 |
Why?
|
| Administration, Intravenous | 1 | 2020 | 165 | 0.040 |
Why?
|
| Liver Neoplasms | 1 | 2009 | 1351 | 0.040 |
Why?
|
| Sodium | 1 | 2020 | 273 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2017 | 293 | 0.030 |
Why?
|
| Fluid Therapy | 1 | 2017 | 145 | 0.030 |
Why?
|
| Allografts | 1 | 2016 | 183 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2017 | 735 | 0.030 |
Why?
|
| Guanine Nucleotides | 1 | 2013 | 13 | 0.030 |
Why?
|
| Hypoxanthine Phosphoribosyltransferase | 1 | 2013 | 34 | 0.030 |
Why?
|
| Biotransformation | 1 | 2013 | 54 | 0.030 |
Why?
|
| Thionucleotides | 1 | 2013 | 21 | 0.030 |
Why?
|
| Drug Evaluation | 1 | 2013 | 102 | 0.030 |
Why?
|
| Xanthine Oxidase | 1 | 2013 | 39 | 0.030 |
Why?
|
| Hyperbilirubinemia | 1 | 2013 | 41 | 0.030 |
Why?
|
| Methyltransferases | 1 | 2013 | 78 | 0.020 |
Why?
|
| Nervous System Diseases | 1 | 2017 | 391 | 0.020 |
Why?
|
| Recurrence | 1 | 2016 | 1408 | 0.020 |
Why?
|
| Acute Kidney Injury | 1 | 2017 | 601 | 0.020 |
Why?
|